Exclusive Licence Agreement with GSK

Apeiron Biologics AG (Apeiron) today announced the signing of an agreement granting GlaxoSmithKline (GSK) exclusive rights to APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme biotherapeutic currently in Phase 1 development for the treatment of the Acute Respiratory Distress Syndrome (ARDS). Press release Presseaussendung  

February 3, 2010
View the Post

Manfred Reichl awarded Business Angel of the Year

On Nov. 17th, one of our major shareholders, business angel and Chairman of the Supervisory Board, DDr. Manfred Reichl has received the award “Business Angel of the Year“. Congratulations!  

November 17, 2009
View the Post